Wugen Presents New Preclinical Data Demonstrating Enhanced Anti-Tumor Activity of WU-NK-101 at the European Hematology Association (EHA) 2022 Hybrid Congress
-- WU-NK-101 exhibited enhanced metabolic flexibility and resistance to tumor microenvironment immunosuppression relative to conventional natural killer (NK) cells -- -- WU-NK-101 demonstrated robust anti-tumor activity in vitro and in…
Read More